Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells

Berger F, Gay E, Pelletier L, Tropel P, Wion D (2004) Development of gliomas: potential role of asymmetrical cell division of neural stem cells. Lancet Oncol 5:511–514

Carpentier AF (2005) Neuro-oncology: the growing role of chemotherapy in glioma. Lancet Neurol. 4:4–5

Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP (2000) Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 97:10173–10178

Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62:3893–3903

Maeda H, Hori S, Nishitoh H et al (2001) Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61:5432–5440

Um SJ, Lee SY, Kim EJ, Myoung J, Namkoong SE, Park JS (2002) Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett 181:11–22

Zhao S, Zhang X, Zhang J et al (2008) Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains. J Chemother 20:253–262

Zhao S, Zhang J, Zhang X, Dong X, Sun X (2008) Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep 35:421–429

Zhao S, Tsuchida T, Kawakami K, Shi C, Kawamoto K (2002) Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol 21:49–55

Dilda PJ, Hogg PJ (2007) Arsenical-based cancer drugs. Cancer Treat Rev 33:542–564

Nguyen T, Yang CS, Pickett CB (2004) The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 37:433–441

Nguyen T, Sherratt PJ, Nioi P, Yang CS, Pickett CB (2005) Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem 280:32485–32492

Konorev EA, Kotamraju S, Zhao H, Kalivendi S, Joseph J, Kalyanaraman B (2002) Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1. Free Radic Biol Med 33:988

Chen TJ, Jeng JY, Lin CW, Wu CY, Chen YC (2006) Quercetin inhibition of ROS-dependent and -independent apoptosis in rat glioma C6 cells. Toxicology 223:113–126

Chen YC, Chow JM, Lin CW, Wu CY, Shen SC (2006) Baicalein inhibition of oxidative-stress-induced apoptosis via modulation of ERKs activation and induction of HO-1 gene expression in rat glioma cells C6. Toxicol Appl Pharmacol 216:263–273

Hara E, Takahashi K, Tominaga T et al (1996) Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors. Biochem Biophys Res Commun 224:153–158

Kim HR, Kim S, Kim EJ et al (2008) Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer 60:47–56

Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89–116

Ma Q, Kinneer K, Bi Y, Chan JY, Kan YW (2004) Induction of murine NAD(P)H:quinone oxidoreductase by 2,3,7,8-tetrachlorodibenzo-p-dioxin requires the CNC (cap ‘n’ collar) basic leucine zipper transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2): cross-interaction between AhR (aryl hydrocarbon receptor) and Nrf2 signal transduction. Biochem J 377(Pt 1):205–213

Cho HY, Reddy SP, Debiase A, Yamamoto M, Kleeberger SR (2005) Gene expression profiling of NRF2-mediated protection against oxidative injury. Free Radic Biol Med 38:325–343

Arlt A, Bauer I, Schafmayer C et al (2009) Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene 28:3983–3996

Kwak MK, Kensler TW (2010) Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244:66–76

Li CQ, Kim MY, Godoy LC, Thiantanawat A, Trudel LJ, Wogan GN (2009) Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells. Proc Natl Acad Sci USA 106:14547–14551

Brouard S, Otterbein LE, Anrather J et al (2000) Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 192:1015–1026

Jozkowicz A, Was H, Dulak J (2007) Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 9:2099–2117

Baranano DE, Rao M, Ferris CD, Snyder SH (2002) Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99:16093–16098

Shen ZX, Chen GQ, Ni JH et al (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354–3360

Wang W, Adachi M, Zhang R, Zhou J, Zhu D (2009) A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas 38:e114–e123